《新股表現》歐康維視生物(01477.HK)高開1.9倍報43元
歐康維視生物-B(01477.HK)暗盤高開91%報28元獲承接,高收43.9元較上市價飆約2倍;該股首掛開報43元,較上市價14.66元,高1.9倍,市前成交1,664萬股。
歐康維視是一家內地眼科醫藥平台公司,致力於識別、開發和商業化同類首創或同類最佳眼科療法。是次來港上市共發售近1.06億股,並已引入包括富達基金及貝萊德基金等14名基石投資者,合共認購5,285.35萬股;其中10%公開發售獲近1,895倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅5%;股份以招股範圍(13.16-14.66元)上限定價,料集資淨額約14.24億元,主要用於核心產品OT-401和其他候選藥物,以及用於根據與市政府所訂合作協議收購蘇州製造設施等。上市聯席保薦人分別為大摩及高盛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.